Golden Pine Ventures Logo

Contact:
Christopher S. Meldrum, Managing Director
E-mail:

For Immediate Release

Golden Pine Ventures appoints Ian Mehr as Managing Director
DURHAM, August 14, 2007–Golden Pine Ventures, LLC, a North Carolina-based venture capital company, today announced the appointment of Ian J. Mehr, Ph.D., as a Managing Director.

Golden Pine Ventures was established in 2004 in Research Triangle Park, North Carolina, by a group of public and private sector biotechnology professionals.  The Company’s mission is to aggressively seek out state-of-the-art technologies developed by leading researchers and grow them into substantial businesses.

“Golden Pine Ventures is focused on discovering exciting, novel technologies that can form the basis of promising, new biotechnology and biomedical companies,” said Christopher S. Meldrum, Managing Director and Founder.  “Ian’s broad experience in business development, strategic alliances, fundraising, and licensing in the biotechnology industry will be instrumental in the support of current and future Golden Pine portfolio companies.”

Prior to joining Golden Pine Ventures, Dr. Mehr served as Vice President of Business Development for Qualyst, Inc., a privately-held biotechnology company focused on novel and proprietary products that increase the efficiency and effectiveness of drug discovery and development.  Dr. Mehr has also led business development at Paradigm Genetics and Laboratory Corporation of America, holding senior roles where he leveraged platform technologies for collaborative applications in drug discovery and development research.  Dr. Mehr received his M.B.A. at Cornell University's Johnson Graduate School of Management, his Ph.D. at Northwestern University's Medical Center, and his B.S. at the University of Illinois Urbana-Champaign.

“The principals of Golden Pine Ventures have a history of past success in the biotechnology and medical device fields,” stated Dr. Mehr.  “I look forward to working with the Golden Pine team to identify new opportunities, and to ensure their growth and success as biotechnology and biomedical businesses.”

About Golden Pine Ventures, LLC
Golden Pine Ventures works with scientists and entrepreneurs to form new portfolio companies, provides the necessary business and management expertise, funds all initial working capital needs, and raises high-valuation follow-on rounds of financing.  Current Golden Pine Ventures’ portfolio companies include: Pique Therapeutics, Kylin Therapeutics, and Exigent Pharmaceuticals.  For more information, please visit www.goldenpineventures.com